26.87
+1.2(+4.67%)
Currency In USD
| Previous Close | 25.67 |
| Open | 25.56 |
| Day High | 27.69 |
| Day Low | 25.21 |
| 52-Week High | 27.69 |
| 52-Week Low | 9.22 |
| Volume | 1.28M |
| Average Volume | 951,264 |
| Market Cap | 1.24B |
| PE | -537.4 |
| EPS | -0.05 |
| Moving Average 50 Days | 19.58 |
| Moving Average 200 Days | 15.86 |
| Change | 1.2 |
If you invested $1000 in AxoGen, Inc. (AXGN) 10 years ago, it would be worth $5,197.29 as of November 23, 2025 at a share price of $26.87. Whereas If you bought $1000 worth of AxoGen, Inc. (AXGN) shares 5 years ago, it would be worth $1,869.87 as of November 23, 2025 at a share price of $26.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
GlobeNewswire Inc.
Oct 15, 2025 11:00 AM GMT
ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will r
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 27, 2025 12:00 PM GMT
ALACHUA, Fla. and TAMPA, Fla., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that managemen
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
GlobeNewswire Inc.
Aug 25, 2025 10:40 AM GMT
FDA PDUFA goal date extended by three monthsALACHUA, Fla. and TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Ac